Skip to main content
. 2022 Jun 22;13:918219. doi: 10.3389/fphar.2022.918219

TABLE 1.

Patient characteristics.

Characteristics No. of patients (%)
Mean age (years) 62.97 ± 10.9
Gender
 Male 87 (62.6%)
 Female 52 (37.4%)
Cancer-related family history
 Yes 4 (2.9%)
 No 135 (97.1%)
Smoking status
 Non-smoker 115 (82.7%)
 Ever smoker 24 (17.3%)
Dosage
 8 mg 73 (52.5%)
 12 mg 66 (47.5%)
ECOG score
 0 38 (27.3%)
 1 85 (61.2%)
 ≥2 16 (11.5%)
Histology
 Adenocarcinoma 77 (55.4%)
 Squamous cell carcinoma 27 (19.4%)
 Small cell 21 (15.1%)
 Others 14 (10.1%)
Clinical stage n (%)
 IIIB 19 (13.7%)
 IV 120 (86.3%)
Treatment line
 <3rd line 47 (33.8%)
 ≥3rd line 92 (66.2%)
EGFR mutation
 Yes 17 (12.2%)
 No 87 (62.6%)
 Unknown 35 (25.2%)
Prior targeted therapy
 Yes 41 (29.5%)
 No 98 (70.5%)
Prior thoracic radiotherapy
 Yes 39 (28.1%)
 No 100 (71.9%)
Prior anti-angiogenesis treatment
 Yes 44 (31.7%)
 No 95 (68.3%)
Surgical history
 Yes 101 (72.7%)
 No 38 (27.3%)